Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 22 Issue 4, April 2023

Targeting galectin-driven regulatory circuits, inspired by the Review on p295.

Cover design: S. Harris

Comment

  • Improved understanding of regulatory requirements by academic researchers can accelerate the translation of new medical interventions to the clinic. Here, we highlight the recommendations of the ‘Strengthening Training of Academia in Regulatory Science’ (STARS) project to improve the interaction and knowledge exchange between academics and regulators, and thereby advance academic drug development.

    • Viktoriia Starokozhko
    • Anne Heß
    • Anna M. G. Pasmooij
    Comment

    Advertisement

Top of page ⤴

News & Analysis

Top of page ⤴

Research Highlights

Top of page ⤴

Reviews

  • Dysregulated protein phosphorylation is implicated in numerous human diseases, but targeting protein phosphates has traditionally proved challenging. Here, Stanford and Bottini provide an overview of protein phosphatase families, focusing on their roles in autoimmunity and tumour immunity. Emerging strategies to tackle these targets and agents in development are assessed.

    • Stephanie M. Stanford
    • Nunzio Bottini
    Review Article
  • Galectins are glycan-binding proteins with broad roles in physiological and pathological processes. Here, Rabinovich and colleagues discuss the therapeutic relevance of galectins to cancer and fibrosis and review the various strategies to target galectins and their progress in clinical trials.

    • Karina V. Mariño
    • Alejandro J. Cagnoni
    • Gabriel A. Rabinovich
    Review Article
Top of page ⤴

Perspectives

  • Investigative toxicology tools and strategies are used in pharmaceutical companies to reduce safety-related attrition in drug development. This Perspective article summarizes the key goals of investigative toxicology, highlights current approaches and discusses selected emerging technologies that have the potential to improve the current safety-testing paradigm.

    • Francois Pognan
    • Mario Beilmann
    • Peter Newham
    Perspective
Top of page ⤴

Search

Quick links